BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, Margaglione M. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5:55-61. [PMID: 17059429 DOI: 10.1111/j.1538-7836.2006.02277.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Gordeuk VR, Key NS, Prchal JT. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. Haematologica. 2019;104:653-658. [PMID: 30872370 DOI: 10.3324/haematol.2018.210732] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
2 Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol 2010;134:82-5. [PMID: 20551270 DOI: 10.1309/AJCP7VO4HAIZYATP] [Cited by in Crossref: 44] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
3 Sène D, Elalamy I, Ancri A, Cacoub P. JAK2V617F mutation is not associated with unexplained recurrent arterial and venous thrombosis. Thrombosis Research 2008;122:427-8. [DOI: 10.1016/j.thromres.2007.12.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
4 El Lakis MA, Pozzi A, Chamieh J, Safadi B. Portomesenteric vein thrombosis after laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass: a 36-case series. Surg Endosc 2017;31:1005-11. [PMID: 27387181 DOI: 10.1007/s00464-016-5078-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
5 Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Grandi AM, Ageno W. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009;113:5617-23. [PMID: 19273837 DOI: 10.1182/blood-2008-12-196014] [Cited by in Crossref: 115] [Cited by in F6Publishing: 92] [Article Influence: 9.6] [Reference Citation Analysis]
6 Hoekstra J, Bresser EL, Smalberg JH, Spaander MCW, Leebeek FWG, Janssen HLA. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms: Portal vein thrombosis and myeloproliferative neoplasms. Journal of Thrombosis and Haemostasis 2011;9:2208-14. [DOI: 10.1111/j.1538-7836.2011.04484.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
7 Famularo G, Minisola G, De Simone C. Mesenteric Vein Thrombosis. Annals of Emergency Medicine 2008;51:685. [DOI: 10.1016/j.annemergmed.2007.11.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Tait C, Baglin T, Watson H, Laffan M, Makris M, Perry D, Keeling D; British Committee for Standards in Haematology. Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 2012;159:28-38. [DOI: 10.1111/j.1365-2141.2012.09249.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 48] [Article Influence: 9.1] [Reference Citation Analysis]
9 Saugel B, Lee M, Feichtinger S, Hapfelmeier A, Schmid RM, Siveke JT. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis. J Thromb Thrombolysis. 2015;40:54-60. [PMID: 25115839 DOI: 10.1007/s11239-014-1124-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
10 Bayraktar Y, Harmanci O, Büyükasik Y, Shorbagi AI, Sungur AH, Boylu CA, Gürgey A, Balkanci F. JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci 2008;53:2778-83. [PMID: 18343999 DOI: 10.1007/s10620-008-0225-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
11 Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. British Journal of Haematology 2010;148:507-21. [DOI: 10.1111/j.1365-2141.2009.08021.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
12 Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, Mcmahon B, Spivak JL, Moliterno AR. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leukemia & Lymphoma 2013;54:1989-95. [DOI: 10.3109/10428194.2012.759656] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
13 Yoo E, Jang J, Park K, Gwak G, Kim H, Kim S, Kim D. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis: THE JAK2 V617F MUTATION IN KOREAN PATIENTS WITH SVT. International Journal of Laboratory Hematology 2011. [DOI: 10.1111/j.1751-553x.2011.01308.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 2012;26:563-71. [PMID: 22076463 DOI: 10.1038/leu.2011.314] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
15 Bittencourt PL, Couto CA, Ribeiro DD. Portal Vein Thrombosis and Budd–Chiari Syndrome. Clinics in Liver Disease 2009;13:127-44. [DOI: 10.1016/j.cld.2008.10.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
16 Colaizzo D, Amitrano L, Tiscia GL, Iannaccone L, Gallone A, Grandone E, Guardascione MA, Margaglione M. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome. Blood Coagul Fibrinolysis. 2008;19:459-462. [PMID: 18600100 DOI: 10.1097/mbc.0b013e3283049662] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
17 Lapecorella M, Tabilio A, Lucchesi A, Napolitano M, Colagrande M, Di Ianni M, Mariani G. Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment. Blood Coagulation & Fibrinolysis 2008;19:453-7. [DOI: 10.1097/mbc.0b013e3283079e46] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogarty PF, Gao S, Garcia-Aguilar J, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Jones KA, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Smith JL, Yee GC, Zakarija A. Venous thromboembolic disease. J Natl Compr Canc Netw 2011;9:714-77. [PMID: 21715723 DOI: 10.6004/jnccn.2011.0062] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
19 Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008;22:2020-8. [DOI: 10.1038/leu.2008.253] [Cited by in Crossref: 91] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
20 Harmanci O, Bayraktar Y. Portal hypertension due to portal venous thrombosis: etiology, clinical outcomes. World J Gastroenterol. 2007;13:2535-2540. [PMID: 17552000 DOI: 10.3748/wjg.v13.i18.2535] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
21 Orr DW, Patel RK, Lea NC, Westbrook RH, O'Grady JG, Heaton ND, Pagliuca A, Mufti GJ, Heneghan MA. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther 2010;31:1330-6. [PMID: 20331577 DOI: 10.1111/j.1365-2036.2010.04299.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
22 Ugo V, Le Gal G, Lecucq L, Mottier D, Oger E; FOR THE EDITH COLLABORATIVE STUDY GROUP. Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism: Letters to the Editor. Journal of Thrombosis and Haemostasis 2008;6:203-5. [DOI: 10.1111/j.1538-7836.2007.02811.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
23 Abd El-hamid N, Taylor RM, Marinello D, Mufti G, Patel R, Mieli-vergani G, Davenport M, Dhawan A. Aetiology and Management of Extrahepatic Portal Vein Obstruction in Children: King's College Hospital Experience. Journal of Pediatric Gastroenterology & Nutrition 2008;47:630-4. [DOI: 10.1097/mpg.0b013e31817b6eea] [Cited by in Crossref: 51] [Cited by in F6Publishing: 6] [Article Influence: 3.9] [Reference Citation Analysis]
24 Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922-4929. [PMID: 18250227 DOI: 10.1182/blood-2007-11-125328] [Cited by in Crossref: 226] [Cited by in F6Publishing: 158] [Article Influence: 17.4] [Reference Citation Analysis]
25 Fallon MB, Batra S. Inherited thrombophilia and the risk of portal vein thrombosis: progress toward individualized anticoagulation in cirrhosis? Clin Gastroenterol Hepatol 2014;12:1813-4. [PMID: 25086188 DOI: 10.1016/j.cgh.2014.07.040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP. Hypercoagulability and Hypofibrinolysis and Risk of Deep Vein Thrombosis and Splanchnic Vein Thrombosis: Similarities and Differences. Arterioscler Thromb Vasc Biol 2011;31:485-93. [DOI: 10.1161/atvbaha.110.213371] [Cited by in Crossref: 34] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
27 Peck-Radosavljevic M, Angermayr B, Datz C, Ferlitsch A, Ferlitsch M, Fuhrmann V, Häfner M, Kramer L, Maieron A, Payer B. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr. 2013;125:200-219. [PMID: 23579878 DOI: 10.1007/s00508-013-0337-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
28 Ponziani FR, Zocco MA, Garcovich M, D'Aversa F, Roccarina D, Gasbarrini A. What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. World J Gastroenterol. 2012;18:5014-5020. [PMID: 23049208 DOI: 10.3748/wjg.v18.i36.5014] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
29 Bittencourt PL, Couto CA, Ribeiro DD. Portal Vein Thrombosis and Budd–Chiari Syndrome. Hematology/Oncology Clinics of North America 2011;25:1049-66. [DOI: 10.1016/j.hoc.2011.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
30 Martínez-Serra J, Maffiotte E, Gutierrez A, Durán MA, Amat JC, Besalduch J. New real-time PCR-based method for the joint genotyping of JAK2 (V617F) with inherited thrombophilic F5 and F2 mutations. Clin Chim Acta 2009;410:59-63. [PMID: 19778528 DOI: 10.1016/j.cca.2009.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Colaizzo D, Amitrano L, Guardascione MA, Favuzzi G, Tiscia GL, D’andrea G, Santacroce R, Grandone E, Margaglione M. Clinical utility of screening for CALR gene exon 9 mutations in patients with splanchnic venous thrombosis. Thromb Haemost 2017;113:1381-2. [DOI: 10.1160/th14-12-1055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
32 Menezes Ferri P, Rodrigues Ferreira A, Tavares Fagundes ED, Guerra Xavier S, Dias Ribeiro D, Fernandes AP, Gomes Borges KB, Liu SM, de Melo MDCB, Roquete MLV, Penna FJ. Evaluation of the Presence of Hereditary and Acquired Thrombophilias in Brazilian Children and Adolescents With Diagnoses of Portal Vein Thrombosis. Journal of Pediatric Gastroenterology & Nutrition 2012;55:599-604. [DOI: 10.1097/mpg.0b013e318261814d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
33 Lauw MN, Bus EW, van Wulfften Palthe AF, Coppens M, Homburg CH, Middeldorp S, van der Schoot CE, Koene HR, Biemond BJ. Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg. Ann Hematol 2012;91:103-7. [PMID: 21484303 DOI: 10.1007/s00277-011-1233-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
34 Colaizzo D, Amitrano L, Guardascione MA, Balzano A, Margaglione M. Janus kinase-2 mutation, cirrhosis and splanchnic vein thrombosis: . European Journal of Gastroenterology & Hepatology 2008;20:245-6. [DOI: 10.1097/meg.0b013e3282f1cff7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Khanna R, Sarin SK. Non-cirrhotic portal hypertension - diagnosis and management. J Hepatol. 2014;60:421-441. [PMID: 23978714 DOI: 10.1016/j.jhep.2013.08.013] [Cited by in Crossref: 170] [Cited by in F6Publishing: 100] [Article Influence: 21.3] [Reference Citation Analysis]
36 Murphy IG, Mitchell EL, Raso-Barnett L, Godfrey AL, Godfrey EM. Imaging features of myeloproliferative neoplasms. Clin Radiol 2017;72:801-9. [PMID: 28615140 DOI: 10.1016/j.crad.2017.05.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
37 Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, Koschmieder S, Matzdorff A, Tiede A, Griesshammer M, Riess H; Haemostasis Working Party of the German Society of Hematology and Oncology., Austrian Society of Hematology and Oncology., Society of Thrombosis and Haemostasis Research. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol 2014;93:1953-63. [PMID: 25307456 DOI: 10.1007/s00277-014-2224-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 6.7] [Reference Citation Analysis]
38 Zarrouk M, Salim S, Elf J, Gottsäter A, Acosta S. Testing for thrombophilia in mesenteric venous thrombosis - Retrospective original study and systematic review. Best Pract Res Clin Gastroenterol 2017;31:39-48. [PMID: 28395787 DOI: 10.1016/j.bpg.2016.11.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
39 Foy P, Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardio Med 2009;11:114-28. [DOI: 10.1007/s11936-009-0012-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
40 Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. Thrombosis 2011;2011:874146. [PMID: 22084670 DOI: 10.1155/2011/874146] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
41 Colaizzo D, Amitrano L, Guardascione MA, Tiscia GL, D'Andrea G, Longo VA, Grandone E, Margaglione M. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res 2013;132:e99-e104. [PMID: 23916380 DOI: 10.1016/j.thromres.2013.07.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
42 Björck M, Koelemay M, Acosta S, Bastos Goncalves F, Kölbel T, Kolkman JJ, Lees T, Lefevre JH, Menyhei G, Oderich G, Esvs Guidelines Committee, Kolh P, de Borst GJ, Chakfe N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Sanddal Lindholt J, Vega de Ceniga M, Vermassen F, Verzini F, Document Reviewers, Geelkerken B, Gloviczki P, Huber T, Naylor R. Editor's Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2017;53:460-510. [PMID: 28359440 DOI: 10.1016/j.ejvs.2017.01.010] [Cited by in Crossref: 190] [Cited by in F6Publishing: 101] [Article Influence: 63.3] [Reference Citation Analysis]
43 Dhiman P, Saxena P. JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis? Case Rep Hematol 2015;2015:373490. [PMID: 25878908 DOI: 10.1155/2015/373490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Fiorini A, Chiusolo P, Rossi E, Za T, De Ritis DG, Ciminello A, Leone G, De Stefano V. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. Am J Hematol 2009;84:126-7. [DOI: 10.1002/ajh.21335] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
45 Casini A, Fontana P, Lecompte T. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost 2013;11:1215-27. [DOI: 10.1111/jth.12265] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
46 Colaizzo D, Amitrano L, Tiscia GL, Grandone E, Guardascione MA, Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007;110:2768-2768. [DOI: 10.1182/blood-2007-05-092502] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
47 Smalberg JH, De Maat MPM, Leebeek FWG. Absence of the JAK2 V617F mutation in patients with arterial thrombosis without overt myeloproliferative disease. Journal of Thrombosis and Haemostasis 2008;6:1606-7. [DOI: 10.1111/j.1538-7836.2008.03081.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Link CS, Platzbecker U, Kroschinsky F, Pannach S, Thiede C, Platzek I, Ehninger G, Schuler MK. Association of Oesophageal Varices and Splanchnic Vein Thromboses in Patients with JAK2-Positive Myeloproliferative Neoplasms: Presentation of Two Cases and Data from a Retrospective Analysis. Case Rep Oncol 2013;6:311-5. [PMID: 23898274 DOI: 10.1159/000352088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Zakeri MA, Bagheripour MH, Iriti M, Dehghan M. Portal Vein Thrombosis after the Consumption of Date Seed Powder: A Case Study. Case Rep Med 2021;2021:6668722. [PMID: 33959162 DOI: 10.1155/2021/6668722] [Reference Citation Analysis]
50 Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. Thromb Haemost 2017;113:1176-83. [DOI: 10.1160/th14-06-0563] [Cited by in Crossref: 57] [Cited by in F6Publishing: 21] [Article Influence: 14.3] [Reference Citation Analysis]
51 Sakr M, Barakat E, Abdelhakam S, Dabbous H, Yousuf S, Shaker M, Eldorry A. Epidemiological aspects of Budd-Chiari in Egyptian patients: a single-center study. World J Gastroenterol. 2011;17:4704-4710. [PMID: 22180713 DOI: 10.3748/wjg.v17.i42.4704] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
52 Ponziani FR, De Stefano V, Gasbarrini A. Viral cirrhosis: an overview of haemostatic alterations and clinical consequences. Mediterr J Hematol Infect Dis 2009;1:e2009033. [PMID: 21415961 DOI: 10.4084/MJHID.2009.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Qi X, Yang Z, Bai M, Shi X, Han G, Fan D. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis: Meta-analysis: JAK2V617F mutation in BCS and PVST. Alimentary Pharmacology & Therapeutics 2011;33:1087-103. [DOI: 10.1111/j.1365-2036.2011.04627.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
54 De Stefano V, Rossi E, Za T, Ciminello A, Betti S, Luzzi C, Leone G, Chiusolo P. JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. Am J Hematol 2011;86:526-8. [DOI: 10.1002/ajh.22024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
55 Singh MM, Pockros PJ. Hematologic and oncologic diseases and the liver. Clin Liver Dis 2011;15:69-87. [PMID: 21111994 DOI: 10.1016/j.cld.2010.09.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
56 Asadzadeh-Aghdaei H, Mashayekhi K, Koushki K, Azimzadeh P, Rostami-Nejad M, Amani D, Chaleshi V, Haftcheshmeh SM, Sahebkar A, Zali MR. V617F-independent upregulation of JAK2 gene expression in patients with inflammatory bowel disease. J Cell Biochem 2019;120:15746-55. [PMID: 31069840 DOI: 10.1002/jcb.28844] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
57 Hmoud B, Singal AK, Kamath PS. Mesenteric venous thrombosis. J Clin Exp Hepatol. 2014;4:257-263. [PMID: 25755568 DOI: 10.1016/j.jceh.2014.03.052] [Cited by in Crossref: 56] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
58 DeLeve LD, Valla DC, Garcia-Tsao G;  American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729-1764. [PMID: 19399912 DOI: 10.1002/hep.22772] [Cited by in Crossref: 599] [Cited by in F6Publishing: 389] [Article Influence: 49.9] [Reference Citation Analysis]
59 Michiels JJ, Commandeur S, Hoogenboom GJ, Wegman JJ, Scholten L, van Rijssel RH, De Raeve H. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Ann Hematol. 2007;86:793-800. [PMID: 17687555 DOI: 10.1007/s00277-007-0351-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
60 Owens CD. JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders. Journal of Vascular Surgery 2010;52:205-7. [DOI: 10.1016/j.jvs.2010.01.097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology 2008;47:1384-93. [DOI: 10.1002/hep.22192] [Cited by in Crossref: 77] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
62 Singal AK, Kamath PS, Tefferi A. Mesenteric venous thrombosis. Mayo Clin Proc. 2013;88:285-294. [PMID: 23489453 DOI: 10.1016/j.mayocp.2013.01.012] [Cited by in Crossref: 112] [Cited by in F6Publishing: 47] [Article Influence: 14.0] [Reference Citation Analysis]
63 Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 2013;162:730-47. [PMID: 23855810 DOI: 10.1111/bjh.12461] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
64 Yonal I, Pinarbası B, Hindilerden F, Hancer VS, Nalcaci M, Kaymakoglu S, Diz-Kucukkaya R. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. J Thromb Thrombolysis 2012;34:388-96. [PMID: 22569900 DOI: 10.1007/s11239-012-0738-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
65 Abel GA, Deangelo DJ, Connors JM, Sholl LM, Mccaffrey RP, Longtine JA. ClinicalJAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol 2008;83:519-20. [DOI: 10.1002/ajh.21159] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
66 Vannucchi AM, Guglielmelli P, Pieri L, Antonioli E, Bosi A. Treatment options for essential thrombocythemia and polycythemia vera. Expert Review of Hematology 2014;2:41-55. [DOI: 10.1586/17474086.2.1.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
67 Shetty S, Ghosh K. Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis – A concise review. Thrombosis Research 2011;127:505-12. [DOI: 10.1016/j.thromres.2010.09.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
68 Fourgeaud C, El Nemer W, Michon Pasturel U, Bonhomme S, Brignier A, Lazareth I, Priollet P. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management]. J Mal Vasc 2015;40:350-8. [PMID: 26362408 DOI: 10.1016/j.jmv.2015.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:1801-12.e7. [PMID: 24793031 DOI: 10.1016/j.cgh.2014.04.026] [Cited by in Crossref: 61] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
70 Rabie H, Othman W, Elsabaawy DM, Elshemy EE, Abdelmageed N, Khalaf FA, Bedair HM. Janus Kinase-2 Mutation Associated Portal Vein Thrombosis Complicating Liver Cirrhosis and Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2021;22:267-75. [PMID: 33507708 DOI: 10.31557/APJCP.2021.22.1.267] [Reference Citation Analysis]
71 Henry Z, Uppal D, Saad W, Caldwell S. Gastric and Ectopic Varices. Clinics in Liver Disease 2014;18:371-88. [DOI: 10.1016/j.cld.2014.01.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
72 Dewitte A, Biais M, Coquin J, Fleureau C, Cassinotto C, Ouattara A, Janvier G. [Diagnosis and management of acute mesenteric ischemia]. Ann Fr Anesth Reanim. 2011;30:410-420. [PMID: 21481561 DOI: 10.1016/j.annfar.2011.02.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
73 Regina S, Herault O, D'alteroche L, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007;5:859-61. [DOI: 10.1111/j.1538-7836.2007.02384.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
74 Colaizzo D, Amitrano L, Iannaccone L, Vergura P, Cappucci F, Grandone E, Guardascione MA, Margaglione M. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 2007;44:412-6. [PMID: 17307838 DOI: 10.1136/jmg.2006.048371] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
75 Harmanci O, Bayraktar Y. Portal hypertension due to portal venous thrombosis: etiology, clinical outcomes. World J Gastroenterol. 2007;13:2535-2540. [PMID: 17552000 DOI: 10.3748/wjq.v13.i18.2535] [Reference Citation Analysis]
76 Colaizzo D, Tiscia GL, Bafunno V, Amitrano L, Vergura P, Lupone MR, Grandone E, Guardascione MA, Margaglione M. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis. Thrombosis Research 2011;128:233-6. [DOI: 10.1016/j.thromres.2011.03.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
77 Valent P, Kern W, Hoermann G, Milosevic Feenstra JD, Sotlar K, Pfeilstöcker M, Germing U, Sperr WR, Reiter A, Wolf D, Arock M, Haferlach T, Horny HP. Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. Int J Mol Sci 2019;20:E789. [PMID: 30759825 DOI: 10.3390/ijms20030789] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
78 Ponziani FR, Zocco MA, Campanale C, Rinninella E, Tortora A, Di Maurizio L, Bombardieri G, De Cristofaro R, De Gaetano AM, Landolfi R. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol. 2010;16:143-155. [PMID: 20066733 DOI: 10.3748/wjg.v16.i2.143] [Cited by in CrossRef: 143] [Cited by in F6Publishing: 92] [Article Influence: 13.0] [Reference Citation Analysis]
79 Austin SK, Lambert JR. The JAK2V617F mutation and thrombosis. British Journal of Haematology 2008;143:307-20. [DOI: 10.1111/j.1365-2141.2008.07258.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
80 Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res. 2012;130 Suppl 1:S1-S3. [PMID: 23026649 DOI: 10.1016/j.thromres.2012.08.259] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
81 Mercier E, Cochery-nouvellon E, Lavigne G, Bertinchant J, Gris J. In support of the revised World Health Organization diagnostic criteria for essential thrombocythemia: JAK2 V617F and premature myocardial infarction: Letters to the Editor. Journal of Thrombosis and Haemostasis 2008;6:206-7. [DOI: 10.1111/j.1538-7836.2007.02822.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
82 Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921-4928. [PMID: 23043069 DOI: 10.1182/blood-2011-09-376517] [Cited by in Crossref: 194] [Cited by in F6Publishing: 128] [Article Influence: 21.6] [Reference Citation Analysis]
83 Prandoni P, Samama MM. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Br J Haematol 2008;141:587-97. [DOI: 10.1111/j.1365-2141.2008.07089.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
84 De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5:708-714. [PMID: 17263783 DOI: 10.1111/j.1538-7836.2007.02424.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 105] [Article Influence: 9.6] [Reference Citation Analysis]
85 Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM, Bonamino M, Zalcberg IR, Spector N. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci. 2010;55:1770-1777. [PMID: 19690956 DOI: 10.1007/s10620-009-0933-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
86 Valla DC. Primary Budd-Chiari syndrome. J Hepatol. 2009;50:195-203. [PMID: 19012988 DOI: 10.1016/j.jhep.2008.10.007] [Cited by in Crossref: 214] [Cited by in F6Publishing: 131] [Article Influence: 16.5] [Reference Citation Analysis]
87 Moerkercke WV, Pauwelyn K, Brugman E, Verhamme M. Cytomegalovirus-associated superior mesenteric vein thrombosis treated with systemic and in-situ thrombolysis: . European Journal of Gastroenterology & Hepatology 2009;21:587-92. [DOI: 10.1097/meg.0b013e3283196b15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
88 Amitrano L, Guardascione MA, Scaglione M, Pezzullo L, Sangiuliano N, Armellino MF, Manguso F, Margaglione M, Ames PR, Iannaccone L, Grandone E, Romano L, Balzano A. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007;102:2464-2470. [PMID: 17958760 DOI: 10.1111/j.1572-0241.2007.01477.x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 129] [Article Influence: 13.8] [Reference Citation Analysis]
89 Kim HK, Chun JM, Huh S. Anticoagulation and delayed bowel resection in the management of mesenteric venous thrombosis. World J Gastroenterol. 2013;19:5025-5028. [PMID: 23946612 DOI: 10.3748/wjg.v19.i30.5025] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
90 Donadini MP, Dentali F, Ageno W. Splanchnic vein thrombosis: new risk factors and management. Thromb Res 2012;129 Suppl 1:S93-6. [PMID: 22682143 DOI: 10.1016/S0049-3848(12)70025-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]